212 related articles for article (PubMed ID: 29039762)
1. Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.
Loaëc N; Attanasio E; Villiers B; Durieu E; Tahtouh T; Cam M; Davis RA; Alencar A; Roué M; Bourguet-Kondracki ML; Proksch P; Limanton E; Guiheneuf S; Carreaux F; Bazureau JP; Klautau M; Meijer L
Mar Drugs; 2017 Oct; 15(10):. PubMed ID: 29039762
[TBL] [Abstract][Full Text] [Related]
2. Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.
Tahtouh T; Elkins JM; Filippakopoulos P; Soundararajan M; Burgy G; Durieu E; Cochet C; Schmid RS; Lo DC; Delhommel F; Oberholzer AE; Pearl LH; Carreaux F; Bazureau JP; Knapp S; Meijer L
J Med Chem; 2012 Nov; 55(21):9312-30. PubMed ID: 22998443
[TBL] [Abstract][Full Text] [Related]
3. Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B.
Deau E; Lindberg MF; Miege F; Roche D; George N; George P; Krämer A; Knapp S; Meijer L
J Med Chem; 2023 Aug; 66(15):10694-10714. PubMed ID: 37487467
[TBL] [Abstract][Full Text] [Related]
4. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
Debdab M; Carreaux F; Renault S; Soundararajan M; Fedorov O; Filippakopoulos P; Lozach O; Babault L; Tahtouh T; Baratte B; Ogawa Y; Hagiwara M; Eisenreich A; Rauch U; Knapp S; Meijer L; Bazureau JP
J Med Chem; 2011 Jun; 54(12):4172-86. PubMed ID: 21615147
[TBL] [Abstract][Full Text] [Related]
5. Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.
Burgy G; Tahtouh T; Durieu E; Foll-Josselin B; Limanton E; Meijer L; Carreaux F; Bazureau JP
Eur J Med Chem; 2013 Apr; 62():728-37. PubMed ID: 23454515
[TBL] [Abstract][Full Text] [Related]
6. Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.
Tahtouh T; Durieu E; Villiers B; Bruyère C; Nguyen TL; Fant X; Ahn KH; Khurana L; Deau E; Lindberg MF; Sévère E; Miege F; Roche D; Limanton E; L'Helgoual'ch JM; Burgy G; Guiheneuf S; Herault Y; Kendall DA; Carreaux F; Bazureau JP; Meijer L
J Med Chem; 2022 Jan; 65(2):1396-1417. PubMed ID: 34928152
[TBL] [Abstract][Full Text] [Related]
7. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
[TBL] [Abstract][Full Text] [Related]
8. Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Lindberg MF; Meijer L
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34205123
[TBL] [Abstract][Full Text] [Related]
9. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315.
Coombs TC; Tanega C; Shen M; Wang JL; Auld DS; Gerritz SW; Schoenen FJ; Thomas CJ; Aubé J
Bioorg Med Chem Lett; 2013 Jun; 23(12):3654-61. PubMed ID: 23642479
[TBL] [Abstract][Full Text] [Related]
11. cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer's disease.
Fant X; Durieu E; Chicanne G; Payrastre B; Sbrissa D; Shisheva A; Limanton E; Carreaux F; Bazureau JP; Meijer L
Mol Pharmacol; 2014 Mar; 85(3):441-50. PubMed ID: 24366666
[TBL] [Abstract][Full Text] [Related]
12. Straightforward Access to a New Class of Dual DYRK1A/CLK1 Inhibitors Possessing a Simple Dihydroquinoline Core.
Ţînţaş ML; Peauger L; Alix F; Papamicaël C; Besson T; Sopková-de Oliveira Santos J; Gembus V; Levacher V
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615235
[TBL] [Abstract][Full Text] [Related]
13. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
[TBL] [Abstract][Full Text] [Related]
14. Quorum sensing inhibitors from Leucetta chagosensis Dendy, 1863.
Mai T; Tintillier F; Lucasson A; Moriou C; Bonno E; Petek S; Magré K; Al Mourabit A; Saulnier D; Debitus C
Lett Appl Microbiol; 2015 Oct; 61(4):311-7. PubMed ID: 26138555
[TBL] [Abstract][Full Text] [Related]
15. New leukotriene B4 receptor antagonist: leucettamine A and related imidazole alkaloids from the marine sponge Leucetta microraphis.
Chan GW; Mong S; Hemling ME; Freyer AJ; Offen PH; DeBrosse CW; Sarau HM; Westley JW
J Nat Prod; 1993 Jan; 56(1):116-21. PubMed ID: 8383730
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
[TBL] [Abstract][Full Text] [Related]
17. Structure and synthesis of 2-aminoimidazole alkaloids from Leucetta and Clathrina sponges.
Koswatta PB; Lovely CJ
Nat Prod Rep; 2011 Mar; 28(3):511-28. PubMed ID: 20981389
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.
Lindberg MF; Deau E; Arfwedson J; George N; George P; Alfonso P; Corrionero A; Meijer L
J Med Chem; 2023 Mar; 66(6):4106-4130. PubMed ID: 36876904
[TBL] [Abstract][Full Text] [Related]
19. Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease.
Warren HT; Saeger HN; Tombari RJ; Chytil M; Rasmussen K; Olson DE
J Med Chem; 2024 May; 67(9):6922-6937. PubMed ID: 38648167
[TBL] [Abstract][Full Text] [Related]
20. Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype.
Walter A; Chaikuad A; Helmer R; Loaëc N; Preu L; Ott I; Knapp S; Meijer L; Kunick C
PLoS One; 2018; 13(5):e0196761. PubMed ID: 29723265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]